Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 20,000 shares of the stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $178.21, for a total transaction of $3,564,200.00. Following the transaction, the director now owns 534,176 shares in the company, valued at $95,195,504.96. The sale was disclosed in a filing with the SEC, which is available through this link.

Illumina, Inc. (NASDAQ ILMN) traded up 3.16% during trading on Thursday, reaching $182.99. 1,201,312 shares of the company’s stock were exchanged. The stock has a market capitalization of $26.72 billion, a PE ratio of 37.04 and a beta of 0.76. The stock has a 50-day moving average of $178.46 and a 200-day moving average of $163.46. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $189.48.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, April 25th. The life sciences company reported $0.64 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.64. Illumina had a return on equity of 21.21% and a net margin of 30.75%. The business had revenue of $598 million during the quarter, compared to analysts’ expectations of $590.51 million. During the same quarter in the prior year, the business earned $0.71 earnings per share. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, equities research analysts anticipate that Illumina, Inc. will post $3.63 EPS for the current year.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

TRADEMARK VIOLATION NOTICE: This article was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/06/22/illumina-inc-ilmn-director-jay-t-flatley-sells-20000-shares.html.

Several large investors have recently added to or reduced their stakes in the company. Advocacy Wealth Management Services LLC bought a new stake in Illumina during the first quarter valued at approximately $102,000. Gemmer Asset Management LLC boosted its stake in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares during the period. Advisory Services Network LLC bought a new stake in Illumina during the first quarter valued at approximately $117,000. Patten Group Inc. boosted its stake in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares during the period. Finally, Bronfman E.L. Rothschild L.P. boosted its stake in Illumina by 3.6% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 1,198 shares of the life sciences company’s stock valued at $204,000 after buying an additional 42 shares during the period. Institutional investors and hedge funds own 96.85% of the company’s stock.

ILMN has been the topic of a number of recent analyst reports. TheStreet upgraded shares of Illumina from a “c+” rating to a “b” rating in a report on Thursday, April 6th. Bank of America Corporation raised their price target on shares of Illumina from $175.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday, April 11th. Leerink Swann restated a “buy” rating on shares of Illumina in a report on Wednesday, April 5th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $191.00 price target on the stock in a report on Tuesday, April 4th. Finally, Vetr cut shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $188.84 price target on the stock. in a report on Monday, March 27th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the stock. Illumina presently has an average rating of “Hold” and a consensus price target of $165.02.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.